北美基因检测市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

北美基因检测市场已按类型(载体检测、诊断检测、新生儿筛查、预测性和症状前检测、产前检测和其他类型)、疾病(阿尔茨海默病、癌症、囊性纤维化、镰状细胞性贫血、杜氏肌营养不良、地中海贫血、亨廷顿氏病和其他疾病)、技术(细胞遗传学检测、生化检测和分子检测)和地理(北美)。

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 9.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

主要因素,如对早期疾病检测和预防的重视、对个性化医疗的需求不断增长、基因检测在肿瘤学中的应用越来越多,以及对直接面向客户的基因检测的大量需求,预计将推动整体市场的增长。

使用各种侵入性和非侵入性技术可以在怀孕早期发现许多遗传疾病。随着这些技术的发展,医生已经能够进行更准确的测试并一次查看多个基因。消费者对安全有效的基因检测的需求正在推动这个市场的增长。此外,对个性化医疗的需求不断增长,基因检测在肿瘤学中的应用越来越多,这也推动了北美基因检测市场的增长。

个人对基因检测的好处和潜力的认识也在提高,以识别和治愈疾病或异常,这是生长基因检测市场的主要原因。

此外,人口老龄化的增加、基因检测领域技术的进步、慢性病病例的增加以及癌症病例的增加,这些都是帮助北美基因检测市场增长的几个因素。

报告范围

根据报告的范围,进行基因测试以确定基因的存在,以及基因组中的特定序列。该基因既可以通过测序直接鉴定,也可以通过各种方法间接鉴定。进行这些基因测试是为了评估个体患某种疾病的风险。

By Type
Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Other Types
By Diseases
Alzheimer's Diseases
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy
Thalassemia
Huntington's Disease
Other Diseases
By Technology
Cytogenetic Testing
Biochemical Testing
Molecular Testing
By Geography
North America
United States
Canada
Mexico

Report scope can be customized per your requirements. Click here.

主要市场趋势

预测性和症状前测试预计将成为预测期内市场的主要贡献者

预测性和症状前测试用于检测与出生后出现的疾病相关的基因突变,通常发生在生命的后期。这样的测试可以帮助有遗传疾病的家庭成员的个人,即使他们在测试时没有任何疾病特征。预测性测试可以帮助识别可能增加个体发展障碍的可能性的突变,例如特定癌症。因此,癌症发病率的上升和对疾病认识的提高预计将导致更多的此类测试,这反过来又有望推动市场。

Number of leukaemia cases from 2018 to 2040, Global

竞争格局

不断增长的遗传病发病率揭示了基因检测及其相关应用的新机遇。预计基因检测从服务驱动市场向产品驱动市场的转变将推动诊断公司扩大业务。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Emphasis on Early Disease Detection and Prevention

      2. 4.2.2 Growing Demand for Personalized Medicine

      3. 4.2.3 Increasing Application of Genetic Testing in Oncology

      4. 4.2.4 Large Demand for Direct-to-Customer Genetic Tests

    3. 4.3 Market Restraints

      1. 4.3.1 High Costs of Genetic Testing

      2. 4.3.2 Potentially Adverse Personal or Societal Consequences

      3. 4.3.3 FDA Strictly Regulates Laboratory Developed Tests (LDTs)

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Carrier Testing

      2. 5.1.2 Diagnostic Testing

      3. 5.1.3 Newborn Screening

      4. 5.1.4 Predictive and Presymptomatic Testing

      5. 5.1.5 Prenatal Testing

      6. 5.1.6 Other Types

    2. 5.2 By Diseases

      1. 5.2.1 Alzheimer's Diseases

      2. 5.2.2 Cancer

      3. 5.2.3 Cystic Fibrosis

      4. 5.2.4 Sickle Cell Anemia

      5. 5.2.5 Duchenne Muscular Dystrophy

      6. 5.2.6 Thalassemia

      7. 5.2.7 Huntington's Disease

      8. 5.2.8 Other Diseases

    3. 5.3 By Technology

      1. 5.3.1 Cytogenetic Testing

      2. 5.3.2 Biochemical Testing

      3. 5.3.3 Molecular Testing

    4. 5.4 By Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 23&Me Inc.

      2. 6.1.2 Abbott Laboratories

      3. 6.1.3 Ariosa Diagnostics Inc.

      4. 6.1.4 Cepheid Inc.

      5. 6.1.5 Illumina Inc.

      6. 6.1.6 Luminex Corporation

      7. 6.1.7 Biorad Laboratories Inc.

      8. 6.1.8 PerkinElmer Inc.

      9. 6.1.9 Quest Diagnostics Incorporated

      10. 6.1.10 F Hoffmann-La Roche Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North-America Genetic Testing Market market is studied from 2018 - 2026.

The North-America Genetic Testing Market is growing at a CAGR of 9.8% over the next 5 years.

Abbott Laboratories, Cepheid Inc., Illumina Inc., 23&Me Inc., F Hoffmann-La Roche Ltd are the major companies operating in North-America Genetic Testing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!